The US FDA has approved a New Drug Application for dihydroergotamine nasal powder for the acute treatment of migraine, with or without aura, in adults. It was first approved in 1946 Clinical evidence In a clinical trial, dihydroergotamine demonstrated a greater headache response compared to placebo (61% vs. 23% at two hours; 70% vs. 28% at four hours).
In two additional clinical trials, dihydroergotamine nasal powder showed fast absorption and achieved high, sustained plasma levels. Dosage and administration Nasal administration only Recommended dose: 5.2 mg (content of one nasal device) Administer into one nostril by squeezing the white air pump device three separate times If needed, repeat the dose at least one hour after the first dose. The maximum dose in 24 hours is 10.4 mg The safety of taking more than four doses within seven days or 12 doses within 30 days has not been…
